Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib Study to Investigate PMD-026 in Women with Triple-Negative Breast Cancer

Trial Profile

A Phase I/Ib Study to Investigate PMD-026 in Women with Triple-Negative Breast Cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs PMD 026 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Phoenix Molecular Designs
  • Most Recent Events

    • 27 Dec 2018 According to a Phoenix Molecular Designs media release, this trial is scheduled to initiate in mid- 2019.
    • 22 Sep 2018 New trial record
    • 18 Sep 2018 According to a Phoenix Molecular Designs media release, the company raises 2.7 dollar M to develop PMD-026 for triple-negative breast cancer.The proceeds from the completed financing and the non-dilutive capital from recent research grants will advance PMD-026 through critical IND-enabling studies and will begin planning around this upcoming study, which the company is excited to initiate.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top